Our portfolio of products
The company is engaged in a wide range of therapy areas including psychiatry, paediatrics, post-operative pain management, anti-infective medicine and emergency medicine. We supply both branded and generic medicines including a wide range of injectable and oral antibiotics.

Flynn focuses on providing medicines for many groups of patients, often by re-discovering and re-energising already established drugs and branded pharmaceutical products. We seek to continue to deliver patient benefits through introducing new products, improving existing formulations or adding new indications.

Slenyto®
Formulation: Paediatric prolonged-release melatonin
Indication: Insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder and/or Smith-Magenis Syndrome, where sleep hygiene measures have been insufficient.
Medikinet® XL
Formulation: Prolonged-release methylphenidate hydrochloride
Indication: Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and over and adults as part of a comprehensive treatment programme when remedial measures alone prove insufficient. Treatment must be initiated and supervised by a doctor specialised in the treatment of ADHD.
Amfexa®
Formulation: Immediate-release dexamfetamine sulfate
Indication: Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years as part of a comprehensive treatment programme under the supervision of a specialist in childhood and/or adolescent behavioural disorders when response to previous methylphenidate treatment is considered clinically inadequate.
Medikinet®
Formulation: Immediate-release methylphenidate hydrochloride
Indication: Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and over as part of a comprehensive treatment programme under supervision of a specialist in childhood behaviour disorders when remedial measures alone prove insufficient.

Request a meeting

Send a virtual meeting request